{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:55:38Z","timestamp":1791424538394,"version":"4.3.3"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":2472,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1038\/ki.2008.496","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T08:06:12Z","timestamp":1223453172000},"page":"465-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":239,"title":["Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?"],"prefix":"10.1016","volume":"75","author":[{"given":"Edward A.","family":"Neuwelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn E.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csanad G.","family":"Varallyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne G.","family":"Watnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2008.496_bb0010","first-page":"510","article-title":"Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors","volume":"23","author":"Varallyay","year":"2002","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1038\/ki.2008.496_bb0015","first-page":"2290","article-title":"An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions","volume":"26","author":"Manninger","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1038\/ki.2008.496_bb0020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1227\/01.NEU.0000255350.71700.37","article-title":"The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study","volume":"60","author":"Neuwelt","year":"2007","journal-title":"Neurosurgery"},{"key":"10.1038\/ki.2008.496_bb0025","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/nbm.906","article-title":"First-pass and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study","volume":"17","author":"Tombach","year":"2004","journal-title":"NMR Biomed"},{"key":"10.1038\/ki.2008.496_bb0030","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00330-004-2405-2","article-title":"Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro","volume":"14","author":"Metz","year":"2004","journal-title":"Eur Radiol"},{"key":"10.1038\/ki.2008.496_bb0035","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/brain\/awn009","article-title":"Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement","volume":"131","author":"Vellinga","year":"2008","journal-title":"Brain"},{"key":"10.1038\/ki.2008.496_bb0040","doi-asserted-by":"crossref","first-page":"C1698","DOI":"10.1152\/ajpcell.00215.2007","article-title":"In vivo leukocyte labeling with intravenous ferumoxides\/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging","volume":"293","author":"Wu","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1038\/ki.2008.496_bb0045","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2990.2004.00557.x","article-title":"Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours","volume":"30","author":"Neuwelt","year":"2004","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1038\/ki.2008.496_bb0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0730-725X(95)00024-B","article-title":"Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil","volume":"13","author":"Jung","year":"1995","journal-title":"Magn Reson Imaging"},{"key":"10.1038\/ki.2008.496_bb0055","series-title":"RSNA Scientific Assembly and Annual Meeting Program","article-title":"A phase I pharmacokinetics and safety study of ferumoxytol, a new blood pool and macrophage specific superparamagnetic iron oxide MR contrast agent","author":"Jacobs","year":"2003"},{"key":"10.1038\/ki.2008.496_bb0060","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000087212","article-title":"Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients","volume":"25","author":"Landry","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2008.496_bb0065","first-page":"777","article-title":"Delivery of virus-sized iron oxide particles to rodent CNS neurons","volume":"34","author":"Neuwelt","year":"1994","journal-title":"Neurosurgery"},{"key":"10.1038\/ki.2008.496_bb0070","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2217\/14750708.2.6.871","article-title":"Imaging brain tumors with ferumoxtran-10, a nanoparticle magnetic resonance contrast agent","volume":"2","author":"Murillo","year":"2005","journal-title":"Therapy"},{"key":"10.1038\/ki.2008.496_bb0075","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1681\/ASN.2007060645","article-title":"New insights into nephrogenic systemic fibrosis","volume":"18","author":"Swaminathan","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.496_bb0080","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1525-139X.2007.00400.x","article-title":"Nephrogenic systemic fibrosis: a sufficient reason to avoid gadolinium-based contrast in all patients with renal impairment?","volume":"21","author":"Willicombe","year":"2008","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2008.496_bb0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMc070248","article-title":"Nephrogenic systemic fibrosis, gadolinium, and iron mobilization","volume":"357","author":"Swaminathan","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2008.496_bb0090","series-title":"American Society of Nephrology 40th Annual Meeting and Scientific Exposition","article-title":"Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subject with chronic kidney diseases (CKD)","author":"Besarab","year":"2007"},{"key":"10.1038\/ki.2008.496_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10334-007-0071-5","article-title":"Imaging in the time of NFD\/NSF: do we have to change our routines concerning renal insufficiency?","volume":"20","author":"Bongartz","year":"2007","journal-title":"MAGMA"},{"key":"10.1038\/ki.2008.496_bb0100","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1021\/cr980440x","article-title":"Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications","volume":"99","author":"Caravan","year":"1999","journal-title":"Chem Rev"},{"key":"10.1038\/ki.2008.496_bb0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/sj.ki.5002338","article-title":"Gadolinium and nephrogenic systemic fibrosis","volume":"72","author":"Grobner","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.496_bb0110","first-page":"1084","article-title":"Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10","volume":"26","author":"Hunt","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1038\/ki.2008.496_bb0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejrad.2008.01.026","article-title":"Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis","volume":"66","author":"Abraham","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1038\/ki.2008.496_bb0120","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2214\/ajr.182.5.1821181","article-title":"Blood pool MR angiography of aortic stent-graft endoleak","volume":"182","author":"Ersoy","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"10.1038\/ki.2008.496_bb0125","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00330-007-0712-0","article-title":"MR angiography with blood pool contrast agents","volume":"17","author":"Bremerich","year":"2007","journal-title":"Eur Radiol"},{"key":"10.1038\/ki.2008.496_bb0130","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/01.rli.0000135980.08491.33","article-title":"Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging","volume":"39","author":"Corot","year":"2004","journal-title":"Invest Radiol"},{"key":"10.1038\/ki.2008.496_bb0135","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jmri.20202","article-title":"Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial","volume":"20","author":"Akella","year":"2004","journal-title":"J Magn Reson Imaging"},{"key":"10.1038\/ki.2008.496_bb0140","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jmri.20235","article-title":"First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent","volume":"21","author":"Li","year":"2005","journal-title":"J Magn Reson Imaging"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815537241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815537241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:47:12Z","timestamp":1758761232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815537241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0085253815537241"],"URL":"https:\/\/doi.org\/10.1038\/ki.2008.496","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/ki.2008.496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}